Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rsv f vaccine + matrix-m1 adjuvant
- Development stage
- Discontinued
- Lead developer
- Novavax
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RSV F vaccine + Matrix-M1 adjuvant is a recombinant subunit nanoparticle vaccine developed by Novavax to prevent respiratory syncytial virus (RSV) infection. The vaccine consists of a recombinant RSV fusion (F) protein antigen, stabilized in its prefusion conformation, and is formulated with Novavax's proprietary saponin-based Matrix-M1 adjuvant. The Matrix-M1 adjuvant is designed to enhance the immune response by stimulating both humoral and cellular (Th1-biased) immunity. Despite showing promise in early trials, the vaccine failed to meet its primary endpoints in large-scale Phase 3 clinical trials for both older adults (Resolve trial) and maternal immunization (Prepare trial), leading to the discontinuation of its development in these specific forms.
- Brand names
- ResVax
- Other names
- RSV F nanoparticle vaccineRSV F subunit vaccineNovavax RSV vaccineRSV F recombinant protein vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on rsv f vaccine + matrix-m1 adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rsv f vaccine + matrix-m1 adjuvant.